BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyGlobeNewsWire · 1 hr ago
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher24/7 Wall Street · 2 days ago
BioNTech, Gilead to test drug combination in advanced breast cancer trialReuters · 2 days ago
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast CancerGlobeNewsWire · 2 days ago
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026GlobeNewsWire · 4 days ago
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026GlobeNewsWire · 5 days agoBioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$2.40 | -$3.70 | Miss |
| May 5, 2026 | -$2.54 | -$2.43 | Beat |
| Mar 10, 2026 | -$0.22 | -$1.44 | Miss |
| Nov 3, 2025 | -$1.12 | -$0.14 | Beat |
| Aug 4, 2025 | -$2.69 | -$1.82 | Beat |
| May 5, 2025 | -$2.48 | -$1.82 | Beat |